未登录

M

Mathias Schmidt

universidade federal do rio grande do sul

H指数:21

被引数:1,420

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CHARACTERIZING SEX-SPECIFIC EFFECTS OF EARLY LIFE ADVERSITY ON THE ADULTHOOD BRAIN TRANSCRIPTOME USING A TRANSLATIONAL MOUSE MODEL

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2024-10-010

PRE

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2024-03-072

OAAI

α- L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial

MOLECULAR THERAPY

IF12

2024-03-011

OA

Integrated long-term efficacy and safety data on enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis type II (MPS II): Updated clinical data from Japan and Brazil

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

A global phase III study of pabinafusp alfa (JR-141) for neuronopathic mucopolysaccharidosis type II: Updated study design

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

A phase I/II clinical trial of JR-441 for treatment of Sanfilippo syndrome type A (MPS IIIA)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2024-02-010

PRE

Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

IF5.5

2022-06-1113

OAAI

Long term efficacy and safety of pabinafusp-alfa (JR-141) in Hunter syndrome (MPS-II): 104-week data from the clinical trials in Japan and Brazil

MOLECULAR GENETICS AND METABOLISM

IF3.5

2022-02-010

PRE

Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid

METABOLIC BRAIN DISEASE

IF3.5

2022-01-2815

OAAI

Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil

MOLECULAR THERAPY

IF12

2021-07-0130

OAAI

Therapy for mucopolysaccharidosis type II with an intravenous blood-brain barrier-crossing enzyme (JR-141): Phase III global clinical trial design

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

Drug delivery across the blood-brain barrier and resultant reduction of heparan sulfate in the cerebrospinal fluid in the patients with Hunter syndrome (MPS II): An integrated analysis of 25-week Japanese and Brazilian data on pabinafusp alfa (JR-141)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

Phase I/II clinical trial design for a novel therapy for mucopolysaccharidosis type I with an intravenously administered blood-brain barrier-crossing enzyme (JR-171)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-010

PREAI

Exploration of the efficacy of pabinafusp-alfa (JR-141) on neurocognitive development in Hunter syndrome (MPS II): 52week data from clinical trials in Japan and Brazil

MOLECULAR GENETICS AND METABOLISM

IF3.5

2021-02-011

PREAI

Hans Gerhard Creutzfeldt (1885-1964) in the Third Reich A reevaluation

IF8.5

2020-07-141

PREAI

Author response: The two lives of neurologist Helmut J. Bauer (1914-2008): Renowned MS specialist and National Socialist

IF8.5

2020-06-020

PRE

Author response: The two lives of neurologist Helmut J. Bauer (1914-2008): Renowned MS specialist and National Socialist

IF8.5

2020-06-020

PRE

Retrospective diagnosis of mental illness: past and present

LANCET PSYCHIATRY

IF24.8

2020-01-0111

OAAI

The two lives of neurologist Helmut J. Bauer (1914-2008) Renowned MS specialist and National Socialist

IF8.5

2019-07-1611

PREAI

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

静脉注射脑穿透性胰岛素受体抗体-iduronidase融合蛋白 (valanafusp alpha) 52周后，严重I型粘多糖贮积症患儿的神经认知和体细胞稳定: 一项开放标签1-2期试验

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2018-07-05111

OAAI